Earnings ·
Solventum reports Q3 adjusted EPS of $1.45, raises full-year guidance to $7.20-$7.30
SOLVSolventum Corp
Solventum reported third-quarter 2026 net sales of $1.9 billion, a 7.0% decrease on a reported basis and a 2.8% decline organically due to the reversal of advance orders placed ahead of an ERP system cutover. Adjusted diluted earnings per share came in at $1.45, down 3.6% year-over-year, while GAAP results included a net loss of $12 million driven by restructuring costs and the absence of a prior-year gain on business sales. The company raised its full-year adjusted EPS guidance to $7.20–$7.30 from $7.10–$7.20 and expects organic sales growth toward the high end of its +2.5% to +3.0% range. Solventum operates in the healthcare sector, providing medical devices, surgical supplies, wound care products, dental solutions, and health information systems.